MinervaX completes a $5M investment round from Sunstone and Novo.

MinervaX, a Copenhagen, Denmark-based biotech company, announced that it raised an investment of EUR 4.4M ($5M).

The funding consists of EUR 3.6M from the Novo Holdings REPAIR Impact Fund for development of therapies to combat antimicrobial resistance (AMR) and of EUR 800k from Sunstone Capital.

Money will be used to help finalize Phase I development of the Company’s protein-only GBS vaccine, targeting pregnant women for the prevention of life-threatening infections in newborns.

MinervaX, established in 2010 and led by CEO Per Fischer, was founded in order to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University.

The company’s investors include Novo A/S, Sunstone Capital, LF Investment, Preseed Ventures A/S (formerly DTU Symbion Innovation A/S) and Lund University Innovation System.